search
Back to results

Early Higher Intravenous Lipid Intake in VLBW Infants

Primary Purpose

Very Low Birth Weight Infant

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Intravenous lipid emulsion
Sponsored by
Belal Alshaikh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Very Low Birth Weight Infant focused on measuring intravenous fat emulsions, preterm infants

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Preterm infants born with birth weight < 1500 g
  2. Appropriate for gestational age (AGA)
  3. Anticipated duration of PN for >7 days

Exclusion Criteria:

  1. Infants with congenital anomalies
  2. Infants with suspected inborn errors of metabolism or family history of inborn error of metabolism
  3. Infants with suspected or confirmed biliary atresia
  4. Infants born small for gestational age (SGA)
  5. Confirmed early sepsis

Sites / Locations

  • Foothills Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

control group

experimental group

Arm Description

Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.

The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth. The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group.

Outcomes

Primary Outcome Measures

The maximum percentage of weight loss
(birth weight-lowest postnatal weight)/birth weight× 100).

Secondary Outcome Measures

Full Information

First Posted
July 9, 2018
Last Updated
December 19, 2021
Sponsor
Belal Alshaikh
search

1. Study Identification

Unique Protocol Identification Number
NCT03594474
Brief Title
Early Higher Intravenous Lipid Intake in VLBW Infants
Official Title
Does Early Higher Intravenous Lipid Intake Decrease Weight Loss in Very Low Birth Weight Infants?
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
August 15, 2018 (Actual)
Primary Completion Date
July 8, 2019 (Actual)
Study Completion Date
October 19, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Belal Alshaikh

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Provision of high and early fat intake may help to reduce the amount of postnatal weight loss in Very Low Birth Weight Infants. It may also help utilize the high amount of protein that is currently recommended to these premature babies. Also, we expect babies who get this appropriate intake to regain their birth weight earlier than others who are on slow fat increase regimen.
Detailed Description
The recommendation of the Pediatric Societies of North America and Europe is that postnatal growth of preterm infants matches the in-utero growth rates of fetuses that remain in utero until full-term. Despite this long-standing recommendation, approximately 43% to 97% of very low birth weight (VLBW, less than 1500 g) infants grow slower than the estimated fetal growth velocity. This slow postnatal growth usually results in extra-uterine growth restriction (EUGR), defined as having a measured growth parameter (weight, length, or head circumference) that is less than 10th percentile of intrauterine growth expectation based on estimated postmenstrual age (PMA) in premature neonates at the time of hospital discharge.4 EUGR is associated with major morbidities such as bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP) and impaired neurodevelopment. Although the etiology of EUGR is multifactorial, inadequate nutrition plays a pivotal role. There are three critical stages of nutrition support in VLBW infants: (1) acute stage during the first 1-3 weeks after birth when infants are on parenteral nutrition, (2) intermediate period when infants are slowly advanced to full enteral nutrition (growing care stage), and (3) the post-discharge stage. Failure to provide adequate nutrition in the acute stage result in cumulative energy and protein deficits that is difficult to reverse in the second stage. Inadequate early postnatal nutrition results in excessive weight loss that cannot be explained by the physiologic contraction of body water alone. The regain of birth weight may need two to three weeks or even longer in preterm infants with excessive postnatal weight loss. Newborn infants born at term normally lose 5-10% of their body weight in the first week of life due to contraction of extracellular water compartment. The proportion of weight loss is significantly higher in VLBW infants. Increased insensible water loss is widely considered as the main cause for additional weight loss in this population. Nevertheless, studies identified low energy intake to be a key driver to excessive weight loss. In fact, an earlier study showed that significant postnatal weight loss occurs mainly in infants whose energy intake is inadequate. A more recent epidemiologic study demonstrated similar postnatal growth trajectories with a minimal crossing of percentiles after the initial weight loss regardless of gestational age at birth. The growth trajectories for infants in that study had similar slopes and growth rates which indicate that proportion of postnatal weight loss is a lead cause for EUGR at discharge. Therefore, we speculate that decreasing the maximum percentage of initial weight loss in the acute stage would keep the preterm infant on a higher growth trajectory that is enough to reduce the incidence of EUGR. Current fat provision regimen for preterm infants include starting parenteral lipid at 12-24 hours of age with 0.5-1 g/kg per day and advancing by 0.5 g/kg/day until reaching 3 g/kg per day. Using early (within one hour of birth) and higher (start at 2 g/kg per day and advance to 3g/kg per day once total fluid intake is increased to 80 ml/kg/day) parenteral fat intake could reduce the cumulative caloric deficit in the acute stage. Because of high-density energy in fat, higher parenteral fat intake will reduce the early energy deficit and enhance protein accretion. The first 2-3 weeks of life offer a critical window to limit postnatal nutritional and energy deficits. Recent study showed that higher energy and fat intakes during the first 2 weeks after birth are associated with a lower incidence of brain lesions and dysmaturation at term equivalent age in preterm neonates. To date, studies of "early aggressive nutrition" in preterm infants have mainly focused on high protein intake to prevent protein catabolism. Nevertheless, provision of high protein intake without enough energy is unlikely to significantly reduce the early loss of protein and fat mass that had been accreted before birth.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Very Low Birth Weight Infant
Keywords
intravenous fat emulsions, preterm infants

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
83 (Actual)

8. Arms, Groups, and Interventions

Arm Title
control group
Arm Type
No Intervention
Arm Description
Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
Arm Title
experimental group
Arm Type
Experimental
Arm Description
The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth. The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group.
Intervention Type
Other
Intervention Name(s)
Intravenous lipid emulsion
Other Intervention Name(s)
Intralipid
Intervention Description
using higher dose of IV lipids after birth
Primary Outcome Measure Information:
Title
The maximum percentage of weight loss
Description
(birth weight-lowest postnatal weight)/birth weight× 100).
Time Frame
Until patient regains birth weight, on average within 14 days

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Preterm infants born with birth weight < 1500 g Appropriate for gestational age (AGA) Anticipated duration of PN for >7 days Exclusion Criteria: Infants with congenital anomalies Infants with suspected inborn errors of metabolism or family history of inborn error of metabolism Infants with suspected or confirmed biliary atresia Infants born small for gestational age (SGA) Confirmed early sepsis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Belal Alshaikh, MD,MSc
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
Foothills Medical Centre
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N2T9
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32798567
Citation
Alburaki W, Yusuf K, Dobry J, Sheinfeld R, Alshaikh B. High Early Parenteral Lipid in Very Preterm Infants: A Randomized-Controlled Trial. J Pediatr. 2021 Jan;228:16-23.e1. doi: 10.1016/j.jpeds.2020.08.024. Epub 2020 Aug 13.
Results Reference
derived

Learn more about this trial

Early Higher Intravenous Lipid Intake in VLBW Infants

We'll reach out to this number within 24 hrs